These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 36504406)

  • 1. Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment.
    Genge A; Pattee GL; Sobue G; Aoki M; Yoshino H; Couratier P; Lunetta C; Petri S; Selness D; Bidani S; Hirai M; Sakata T; Salah A; Apple S; Wamil A; Kalin A; Jackson CE
    Muscle Nerve; 2023 Feb; 67(2):124-129. PubMed ID: 36504406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Edaravone Oral Suspension: A Neuroprotective Agent to Treat Amyotrophic Lateral Sclerosis.
    Singh P; Belliveau P; Towle J; Neculau AE; Dima L
    Am J Ther; 2024 May-Jun 01; 31(3):e258-e267. PubMed ID: 38691665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
    ;
    Lancet Neurol; 2017 Jul; 16(7):505-512. PubMed ID: 28522181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis.
    Witzel S; Maier A; Steinbach R; Grosskreutz J; Koch JC; Sarikidi A; Petri S; Günther R; Wolf J; Hermann A; Prudlo J; Cordts I; Lingor P; Löscher WN; Kohl Z; Hagenacker T; Ruckes C; Koch B; Spittel S; Günther K; Michels S; Dorst J; Meyer T; Ludolph AC;
    JAMA Neurol; 2022 Feb; 79(2):121-130. PubMed ID: 35006266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A safety analysis of edaravone (MCI-186) during the first six cycles (24 weeks) of amyotrophic lateral sclerosis (ALS) therapy from the double-blind period in three randomized, placebo-controlled studies.
    Kalin A; Medina-Paraiso E; Ishizaki K; Kim A; Zhang Y; Saita T; Wasaki M
    Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):71-79. PubMed ID: 28872919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of Edaravone Oral Suspension in Patients With Amyotrophic Lateral Sclerosis.
    Shimizu H; Nishimura Y; Shiide Y; Akimoto M; Yashiro M; Ueda M; Hirai M; Yoshino H; Mizutani T; Kanai K; Kano O; Kimura H; Sekino H; Ito K
    Clin Ther; 2023 Dec; 45(12):1251-1258. PubMed ID: 37953075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcomes of edaravone in amyotrophic lateral sclerosis in South Korea: 72-week observational study.
    Park JM; Park D; Kim HJ; Park JS
    BMC Neurol; 2022 Jul; 22(1):260. PubMed ID: 35836136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral Edaravone - Introducing a Flexible Treatment Option for Amyotrophic Lateral Sclerosis.
    Pattee GL; Genge A; Couratier P; Lunetta C; Sobue G; Aoki M; Yoshino H; Jackson CE; Wymer J; Salah A; Nelson S
    Expert Rev Neurother; 2023; 23(10):859-866. PubMed ID: 37646130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Open-label 24-week extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis.
    WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 19 STUDY GROUP
    Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):55-63. PubMed ID: 28872920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Logistics and safety of edaravone treatment for amyotrophic lateral sclerosis: experience in Argentina.
    Quarracino C; Bendersky M; Rey R; Rodríguez GE
    Acta Neurol Belg; 2021 Dec; 121(6):1519-1523. PubMed ID: 32436077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal function in amyotrophic lateral sclerosis patients on long-term treatment with edaravone.
    Kakimoto A; Ishizaki M; Ueyama H; Maeda Y; Ueda M
    Medicine (Baltimore); 2021 May; 100(21):e26127. PubMed ID: 34032759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of the US Safety Data for Edaravone (Radicava
    Genge A; Brooks BR; Oskarsson B; Kalin A; Ji M; Apple S; Bower L
    Drugs R D; 2022 Sep; 22(3):205-211. PubMed ID: 35723868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of edaravone in treatment of amyotrophic lateral sclerosis-a systematic review and meta-analysis.
    Luo L; Song Z; Li X; Huiwang ; Zeng Y; Qinwang ; Meiqi ; He J
    Neurol Sci; 2019 Feb; 40(2):235-241. PubMed ID: 30483992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of intervention with intravenous edaravone in Study 19 on hospitalization, tracheostomy, ventilation, and death in patients with amyotrophic lateral sclerosis.
    Brooks BR; Pioro EP; Sakata T; Takahashi F; Hagan M; Apple S
    Muscle Nerve; 2023 Oct; 68(4):397-403. PubMed ID: 37525592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Edaravone: a new hope for deadly amyotrophic lateral sclerosis.
    Bhandari R; Kuhad A; Kuhad A
    Drugs Today (Barc); 2018 Jun; 54(6):349-360. PubMed ID: 29998226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of edaravone therapy in Korean amyotrophic lateral sclerosis (ALS) patients.
    Park JM; Kim SY; Park D; Park JS
    Neurol Sci; 2020 Jan; 41(1):119-123. PubMed ID: 31471712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of clinical outcome and safety profile of edaravone in treatment of amyotrophic lateral sclerosis: a 72-week single-center experience.
    Ismail II; Massoud F; Kamel WA; Al-Hashel JY
    Acta Neurol Belg; 2021 Dec; 121(6):1591-1597. PubMed ID: 32651875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of Use and Safety of Edaravone for Amyotrophic Lateral Sclerosis in the Veterans Affairs Health Care System.
    Vu M; Tortorice K; Zacher J; Dong D; Hur K; Zhang R; Good CB; Glassman PA; Cunningham FE
    JAMA Netw Open; 2020 Oct; 3(10):e2014645. PubMed ID: 33017028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radicava (edaravone) for amyotrophic lateral sclerosis: US experience at 1 year after launch.
    Jackson C; Heiman-Patterson T; Kittrell P; Baranovsky T; McAnanama G; Bower L; Agnese W; Martin M
    Amyotroph Lateral Scler Frontotemporal Degener; 2019 Nov; 20(7-8):605-610. PubMed ID: 31364409
    [No Abstract]   [Full Text] [Related]  

  • 20. Evaluation of Pharmacokinetics, Safety, and Drug-Drug Interactions of an Oral Suspension of Edaravone in Healthy Adults.
    Shimizu H; Nishimura Y; Shiide Y; Matsuda H; Akimoto M; Matsuda M; Nakamaru Y; Kato Y; Kondo K
    Clin Pharmacol Drug Dev; 2021 Oct; 10(10):1174-1187. PubMed ID: 33704925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.